# Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)

> **NCT02496039** · PHASE4 · TERMINATED · sponsor: **Avanir Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Pseudobulbar Affect (Involuntary Laughing and/or Crying)

## Interventions

- **DRUG:** NUEDEXTA®

## Key facts

- **NCT ID:** NCT02496039
- **Lead sponsor:** Avanir Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated prematurely because of difficulty with recruiting.
- **Last updated:** 2017-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02496039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02496039, "Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02496039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*